Tenaya Therapeutics Appoints New Directors at Annual Meeting

An update from Tenaya Therapeutics ( (TNYA) ) is now available.

On May 28, 2025, Tenaya Therapeutics, Inc. held its annual meeting of stockholders where key decisions were made. The election of Class I Directors resulted in the appointment of David Goeddel, Jeffrey T. Walsh, and R. Sanders Williams to serve until the 2028 annual meeting. Additionally, the stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to provide stability in the company’s governance and financial oversight.

The most recent analyst rating on (TNYA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Tenaya Therapeutics stock, see the TNYA Stock Forecast page.

Spark’s Take on TNYA Stock

According to Spark, TipRanks’ AI Analyst, TNYA is a Underperform.

Tenaya Therapeutics’ overall score is primarily impacted by its financial performance, characterized by pre-revenue status and high cash burn due to R&D expenses. Technical indicators highlight a bearish trend, with the stock trading below key moving averages and near oversold conditions. Valuation metrics reflect non-profitability and lack of dividend yield, typical for early-stage biotech firms.

To see Spark’s full report on TNYA stock, click here.

More about Tenaya Therapeutics

Tenaya Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies for heart disease. The company is involved in creating treatments that address the underlying causes of heart failure, aiming to improve patient outcomes.

Average Trading Volume: 3,561,703

Technical Sentiment Signal: Sell

Current Market Cap: $72.29M

See more insights into TNYA stock on TipRanks’ Stock Analysis page.